Full-Time

Histotechnologist

Confirmed live in the last 24 hours

Natera

Natera

1,001-5,000 employees

Genetic testing and diagnostics solutions provider

Biotechnology
Healthcare

Compensation Overview

$44.75 - $55Hourly

Entry, Junior

San Carlos, CA, USA

Category
Diagnostics & Laboratory Professionals
Medical, Clinical & Veterinary
Requirements
  • Associates degree and completion of a certified clinical program in medical laboratory sciences in histopathology or equivalent.
  • ASCP certified HT/HTL.
Responsibilities
  • Preparation of tissues and stained slides of a high quality.
  • Troubleshooting of technical problems related to sample preparation
  • Participation and compliance with state and federal regulations..
  • Provide professional support for Clinical Trial team by means of accurate data collection, organization, and transfer.
  • Performs other duties as assigned.

Natera focuses on genetic testing and diagnostics, providing advanced solutions for cancer patients, transplant patients, and individuals assessing hereditary health risks. Their main technology, cell-free DNA (cfDNA) testing, analyzes DNA fragments in the blood to detect minimal traces of cancer and monitor organ health. Natera stands out by offering specialized tests like the Signatera ctDNA test and Panorama NIPT, along with genetic counseling services, directly to healthcare providers and patients. The company's goal is to improve patient care through precise genetic insights that support informed medical decisions.

Company Stage

IPO

Total Funding

$149.9M

Headquarters

Austin, Texas

Founded

2004

Growth & Insights
Headcount

6 month growth

9%

1 year growth

25%

2 year growth

66%
Simplify Jobs

Simplify's Take

What believers are saying

  • Signatera test detects cancer recurrence earlier than traditional imaging.
  • Prospera Heart's DQS improves accuracy in transplant rejection risk assessment.
  • Natera's extensive cfDNA experience supports innovation across multiple health sectors.

What critics are saying

  • Hindenburg report alleges deceptive sales practices, risking legal and reputational issues.
  • New testing features may face slow adoption by healthcare providers.
  • Fetal RhD test demand may decline post-RhIg shortage, affecting sales.

What makes Natera unique

  • Natera's cfDNA technology is pivotal in prenatal and cancer diagnostics.
  • The Donor Quantity Score (DQS) enhances Prospera Heart's transplant rejection detection.
  • Natera's fetal RhD test addresses RhIg shortages, offering unique prenatal solutions.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible medical plans

Investment options

Time off

Workplace perks